Plain-English translation of NCT05501899 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a naturally occurring supplement, can help protect the liver during chemotherapy treatment for acute lymphoblastic leukemia (ALL). Asparaginase is a key chemotherapy drug used to treat ALL, but it can sometimes damage the liver. Researchers want to see if taking during treatment can reduce this liver damage while still helping the cancer treatment work well.
Asparaginase is an important part of ALL treatment, but it can cause serious liver problems in some patients, especially in certain ethnic groups. This study aims to find out if the medication can prevent or reduce these liver injuries without affecting how well the cancer treatment works.
You likely qualify if…
You likely don't qualify if…
You would take by mouth during the early phases of your ALL chemotherapy treatment (Induction and Consolidation phases). Researchers would monitor your liver function with regular blood tests and ultrasound imaging to see if the supplement helps protect your liver. The study also compares your outcomes to records from similar patients who did not receive the supplement.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States